High-risk disease biology in multiple myeloma

1 Views

07/01/23

Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the importance of identifying patients with multiple myeloma with high-risk disease, based on clinical as well genomic features. Despite previous exclusion from clinical trials, recent assessments of T-cell redirecting therapies have included patients with clinical high-risk disease and such patients receiving lenalidomide, dexamethasone, and eculizumab have shown similar responses to patients without high-risk markers. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.